Table 3.
Study visits.
| Assessment method | Screening | Inclusion | 180-day follow-up | 365-day follow-up | Unscheduled follow-up | |
|---|---|---|---|---|---|---|
| Range | 0 | 0 | ±20 days | ±20 days | ||
| NIHSS | X | X | ||||
| ECG | X | X | X | X | ||
| MRI or NCCT | X | |||||
| MRA or CTA | X | |||||
| Colour duplex of the precerebral arteries | X | |||||
| 24-h ECG monitoring | X | |||||
| Echocardiography TTE/TEE | X | |||||
| Blood labs | X | X | ||||
| Modified Rankin Scale mRS | X | X | ||||
| Pre-stroke mRS | X | |||||
| Pre-stroke Barthel Index | X | |||||
| Barthel Index | X | |||||
| EuroQol 5D-5L | X | X | ||||
| Concomitant medication | X | X | X | X | X | |
| Recurrent stroke/TIA | X | X | X | X | ||
| Major cardiovascular events | X | X | X | X | ||
| Adverse events | X | X | X | X | X | |
NIHSS: National Institute of Health Stroke Scale; ECG: electrocardiography; MRI: magnetic resonance imaging; CT: computer tomography; TTE: transthoracic echocardiography; TEE: transoesophageal echocardiography; EuroQOL: European Quality of Life Scale.